Drugs / Human (allogeneic) iPS-cell-derived cardiomyocyte
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05566600 | Oct 2022 → Dec 2024 | heart failure | HELP Therapeutics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human (allogeneic) iPS-cell-derived cardiomyocyte | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05566600 ↗ |
| Route | Other | “administrated intramyocardially” NCT05566600 ↗ |